Enfermedades Infecciosas y Microbiología Clínica ( IF 2.5 ) Pub Date : 2019-12-24 , DOI: 10.1016/j.eimc.2019.10.016 Oscar Len 1 , Ibai Los-Arcos 1 , José María Aguado 2 , Marino Blanes 3 , Marta Bodro 4 , Jordi Carratalà 5 , Elisa Cordero 6 , María Carmen Fariñas 7 , Mario Fernández-Ruiz 2 , Jesús Fortún 8 , Joan Gavaldà 1 , Francisco López-Medrano 2 , Rogelio López-Vélez 8 , Carlos Lumbreras 2 , Beatriz Mahillo 9 , María Ángeles Marcos 10 , Pilar Martin-Dávila 8 , José Miguel Montejo 11 , Asunción Moreno 4 , Patricia Muñoz 12 , Francesca Norman 8 , José Luis Pérez-Sáenz 13 , Tomás Pumarola 1 , Núria Sabé 5 , Rafael San-Juan 2 , Elisa Vidal 14 , Beatriz Domínguez-Gil 9 ,
The immunosuppressive treatment that recipients receive from a solid organ transplantation hinders the defensive response to infection. Its transmission from the donor can cause dysfunction or loss of the graft and even death of the recipient if proper preventive measures are not established. This potential risk should be thoroughly evaluated to minimise the risk of infection transmission from donor to recipient, especially with organ transplantation from donors with infections, without increasing graft dysfunction and morbidity and mortality in the recipient. This document aims to review current knowledge about infection screening in potential donors and offer clinical and microbiological recommendations about the use of organs from donors with infection based on available scientific evidence.
中文翻译:
西班牙传染病和临床微生物学学会 (SEIMC) 和国家移植组织 (ONT) 的移植感染研究组 (GESITRA) 就传染病相关实体器官捐献者的选择标准达成的共识声明的执行摘要.
接受者从实体器官移植中接受的免疫抑制治疗阻碍了对感染的防御反应。如果不采取适当的预防措施,它从供体传播会导致移植物功能障碍或丢失,甚至受体死亡。应彻底评估这种潜在风险,以最大限度地减少从供体到受体的感染传播风险,尤其是从感染供体移植器官时,不会增加受者的移植物功能障碍和发病率和死亡率。本文件旨在回顾有关潜在捐赠者感染筛查的当前知识,并根据现有科学证据提供有关使用感染捐赠者器官的临床和微生物学建议。